Literature DB >> 18642892

Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.

Alan P Kozikowski1, Subhasish Tapadar, Doris N Luchini, Ki Hwan Kim, Daniel D Billadeau.   

Abstract

A series of hydroxamate based HDAC inhibitors containing a phenylisoxazole as the CAP group has been synthesized using nitrile oxide cycloaddition chemistry. An HDAC6 selective inhibitor having a potency of approximately 2 picomolar was identified. Some of the compounds were examined for their ability to block pancreatic cancer cell growth and found to be about 10-fold more potent than SAHA. This research provides valuable, new molecular probes for use in exploring HDAC biology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18642892      PMCID: PMC3913184          DOI: 10.1021/jm8002894

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  25 in total

Review 1.  Anticancer activities of histone deacetylase inhibitors.

Authors:  Jessica E Bolden; Melissa J Peart; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

2.  A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.

Authors:  Yufeng Chen; Miriam Lopez-Sanchez; Doris N Savoy; Daniel D Billadeau; Geoffrey S Dow; Alan P Kozikowski
Journal:  J Med Chem       Date:  2008-06-26       Impact factor: 7.446

Review 3.  The TAFs in the HAT.

Authors:  K Struhl; Z Moqtaderi
Journal:  Cell       Date:  1998-07-10       Impact factor: 41.582

Review 4.  Histone acetylation in chromatin structure and transcription.

Authors:  M Grunstein
Journal:  Nature       Date:  1997-09-25       Impact factor: 49.962

5.  Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.

Authors:  William Kevin Kelly; Andrew X Zhu; Howard Scher; Tracey Curley; Mary Fallon; Susan Slovin; Lawrence Schwartz; Steve Larson; William Tong; Beryl Hartley-Asp; Cinzia Pellizzoni; Maurizio Rocchetti
Journal:  Clin Cancer Res       Date:  2003-06       Impact factor: 12.531

6.  Neuroprotection by histone deacetylase-related protein.

Authors:  Brad E Morrison; Nazanin Majdzadeh; Xiaoguang Zhang; Aaron Lyles; Rhonda Bassel-Duby; Eric N Olson; Santosh R D'Mello
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

7.  A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells.

Authors:  Lalji K Gediya; Pankaj Chopra; Puranik Purushottamachar; Neha Maheshwari; Vincent C O Njar
Journal:  J Med Chem       Date:  2005-07-28       Impact factor: 7.446

8.  Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors.

Authors:  Hongyu Zhao; Gang Liu; Zhili Xin; Michael D Serby; Zhonghua Pei; Bruce G Szczepankiewicz; Philip J Hajduk; Cele Abad-Zapatero; Charles W Hutchins; Thomas H Lubben; Stephen J Ballaron; Deanna L Haasch; Wiweka Kaszubska; Cristina M Rondinone; James M Trevillyan; Michael R Jirousek
Journal:  Bioorg Med Chem Lett       Date:  2004-11-15       Impact factor: 2.823

Review 9.  Histone deacetylase inhibitors.

Authors:  Paul A Marks; Victoria M Richon; Thomas Miller; William Kevin Kelly
Journal:  Adv Cancer Res       Date:  2004       Impact factor: 6.242

Review 10.  Pancreatic cancer.

Authors:  Donghui Li; Keping Xie; Robert Wolff; James L Abbruzzese
Journal:  Lancet       Date:  2004-03-27       Impact factor: 79.321

View more
  60 in total

1.  Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

Authors:  Loredana Santo; Teru Hideshima; Andrew L Kung; Jen-Chieh Tseng; David Tamang; Min Yang; Matthew Jarpe; John H van Duzer; Ralph Mazitschek; Walter C Ogier; Diana Cirstea; Scott Rodig; Homare Eda; Tyler Scullen; Miriam Canavese; James Bradner; Kenneth C Anderson; Simon S Jones; Noopur Raje
Journal:  Blood       Date:  2012-01-19       Impact factor: 22.113

2.  PKC alpha regulates Sendai virus-mediated interferon induction through HDAC6 and β-catenin.

Authors:  Jianzhong Zhu; Carolyn B Coyne; Saumendra N Sarkar
Journal:  EMBO J       Date:  2011-09-27       Impact factor: 11.598

3.  Fam65b is important for formation of the HDAC6-dysferlin protein complex during myogenic cell differentiation.

Authors:  Anuradha Balasubramanian; Genri Kawahara; Vandana A Gupta; Anete Rozkalne; Ariane Beauvais; Louis M Kunkel; Emanuela Gussoni
Journal:  FASEB J       Date:  2014-03-31       Impact factor: 5.191

4.  Oxime-based click chemistry in the development of 3-isoxazolecarboxylic acid containing inhibitors of Yersinia pestis protein tyrosine phosphatase, YopH.

Authors:  Medhanit Bahta; Terrence R Burke
Journal:  ChemMedChem       Date:  2011-06-10       Impact factor: 3.466

5.  HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade.

Authors:  Y J Kim; C B Greer; K R Cecchini; L N Harris; D P Tuck; T H Kim
Journal:  Oncogene       Date:  2013-02-25       Impact factor: 9.867

6.  Characterization of phytochemicals and evaluation of anti-cancer potential of Blumea eriantha DC.

Authors:  Mohini Gore; N S Desai
Journal:  Physiol Mol Biol Plants       Date:  2014-07-03

7.  Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.

Authors:  Chung-Pu Wu; Ya-Ju Hsieh; Megumi Murakami; Shahrooz Vahedi; Sung-Han Hsiao; Ni Yeh; An-Wei Chou; Yan-Qing Li; Yu-Shan Wu; Jau-Song Yu; Suresh V Ambudkar
Journal:  Biochem Pharmacol       Date:  2018-07-17       Impact factor: 5.858

8.  HSP90 inhibitor geldanamycin reverts IL-13- and IL-17-induced airway goblet cell metaplasia.

Authors:  Alejandro A Pezzulo; Rosarie A Tudas; Carley G Stewart; Luis G Vargas Buonfiglio; Brian D Lindsay; Peter J Taft; Nicholas D Gansemer; Joseph Zabner
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

9.  Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.

Authors:  Rong He; Yufeng Chen; Yihua Chen; Andrei V Ougolkov; Jin-San Zhang; Doris N Savoy; Daniel D Billadeau; Alan P Kozikowski
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

10.  1-(3-p-Tolyl-isoxazol-5-yl)cyclo-hexa-nol.

Authors:  Ouafaa Khalil; Khalid Bougrin; Rachid Benhida; Mohamed Soufiaoui; Lahcen El Ammari
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.